About Dermira (NASDAQ:DERM)
Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200
Debt
Debt-to-Equity Ratio1.87%
Current Ratio5.28%
Quick Ratio5.28%
Price-To-Earnings
Trailing P/E Ratio-1.96
Forward P/E Ratio-1.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.54 million
Price / Sales79.31
Cash FlowN/A
Price / CashN/A
Book Value$3.59 per share
Price / Book2.40
Profitability
EPS (Most Recent Fiscal Year)($4.39)
Net Income$-303,260,000.00
Net Margins-6,678.29%
Return on Equity-62.07%
Return on Assets-29.13%
Miscellaneous
Employees162
Outstanding Shares41,820,000
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira (NASDAQ:DERM) released its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.25) by $0.09. The biopharmaceutical company earned $1.34 million during the quarter, compared to analysts' expectations of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. View Dermira's Earnings History.
What price target have analysts set for DERM?
7 analysts have issued twelve-month price objectives for Dermira's stock. Their predictions range from $19.00 to $48.00. On average, they expect Dermira's stock price to reach $32.7143 in the next year. View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. Cantor Fitzgerald analysts commented, "We remain positive on DERM’s stock following a group investor dinner we held on 3/26/18 with COO & CFO Andrew Guggenhime and VP of IR Ian Clements." (3/27/2018)
- 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (3/16/2018)
- 3. Mizuho analysts commented, "We can attest that Dermira has been investing in pre-launch activities and had a strong presence at the AAD 2018 conference across all three of its key assets in acne, hyperhidrosis, and atopic dermatitis. We summarize 4Q:17 results in Exhibit 1 below. We reiterate our Buy rating in front of the binary acne read-out, which if positive, could drive significant upside to the stock. Data are expected in 1Q:18." (2/23/2018)
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Dova Pharmaceuticals (DOVA), AMAG Pharmaceuticals (AMAG), Adamas Pharmaceuticals (ADMS), Rocket Pharmaceuticals (RCKT), Endocyte (ECYT), Lannett (LCI), Ziopharm Oncology (ZIOP), Rhythm Pharmaceuticals (RYTM), Arrowhead Pharmaceuticals (ARWR), BeyondSpring (BYSI), Geron (GERN), Odonate Therapeutics (ODT), Reata Pharmaceuticals (RETA), Five Prime Therapeutics (FPRX), Clementia Pharmaceuticals (CMTA), Kura Oncology (KURA), Keryx Biopharmaceuticals (KERX) and Aduro BioTech (ADRO).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)
- Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)
- Mr. Christopher M. Griffith, Co-Founder & Sr. VP of Corp. Devel. & Strategy (Age 42)
- Mr. Andrew L. Guggenhime, COO, CFO & Principal Accounting Officer (Age 50)
- Mr. Luis C. Peña, Chief Devel. Officer (Age 55)
Has Dermira been receiving favorable news coverage?
Press coverage about DERM stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dermira earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.78 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Dermira's major shareholders?
Dermira's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
WELLINGTON MANAGEMENT GROUP LLP
(10.50%),
PRUDENTIAL FINANCIAL INC
(2.30%) and FMR LLC (0.30%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Luis C Pena, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $8.61.
How big of a company is Dermira?
Dermira has a market capitalization of $361.34 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe.
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (DERM)
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dermira (NASDAQ:DERM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Dermira in the last 12 months. Their average twelve-month price target is $32.7143, suggesting that the stock has a possible upside of 279.96%. The high price target for DERM is $48.00 and the low price target for DERM is $19.00. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.71 | 2.71 | 2.50 | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $32.7143 | $32.7143 | $42.1667 | $44.40 |
| Price Target Upside: | 279.96% upside | 273.02% upside | 56.40% upside | 72.16% upside |
Dermira (NASDAQ:DERM) Consensus Price Target History
Dermira (NASDAQ:DERM) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Dermira (NASDAQ:DERM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Dermira (NASDAQ DERM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 94.93%
Dermira (NASDAQ DERM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | David E Cohen | Director | Sell | 600 | $25.85 | $15,510.00 | |  |
| 3/1/2018 | Eugene A Bauer | Insider | Sell | 500 | $25.32 | $12,660.00 | | |
| 2/1/2018 | David E Cohen | Director | Sell | 600 | $28.87 | $17,322.00 | 30,282 | |
| 2/1/2018 | Eugene A Bauer | Insider | Sell | 3,000 | $28.55 | $85,650.00 | 5,802 | |
| 1/2/2018 | Christopher M Griffith | SVP | Sell | 18,458 | $27.05 | $499,288.90 | | |
| 1/2/2018 | David E Cohen | Director | Sell | 600 | $28.03 | $16,818.00 | | |
| 1/2/2018 | Eugene A Bauer | Insider | Sell | 3,000 | $27.07 | $81,210.00 | 5,802 | |
| 12/18/2017 | Eugene A. Bauer | Insider | Sell | 3,000 | $27.34 | $82,020.00 | | |
| 12/13/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $27.51 | $137,550.00 | | |
| 12/1/2017 | David E Cohen | Director | Sell | 600 | $25.49 | $15,294.00 | | |
| 11/2/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $27.52 | $137,600.00 | | |
| 11/1/2017 | David E Cohen | Director | Sell | 600 | $26.82 | $16,092.00 | | |
| 10/11/2017 | Eugene A Bauer | Insider | Sell | 7,500 | $30.04 | $225,300.00 | | |
| 10/10/2017 | Thomas G Wiggans | CEO | Sell | 5,000 | $27.52 | $137,600.00 | | |
| 10/2/2017 | David E Cohen | Director | Sell | 600 | $26.99 | $16,194.00 | 32,682 | |
| 9/18/2017 | Thomas G. Wiggans | CEO | Sell | 9,500 | $27.51 | $261,345.00 | | |
| 9/1/2017 | David E Cohen | Director | Sell | 600 | $23.56 | $14,136.00 | 33,282 | |
| 8/28/2017 | David E Cohen | Director | Sell | 600 | $23.81 | $14,286.00 | 33,882 | |
| 8/14/2017 | Fred B Craves | Director | Buy | 30,000 | $23.03 | $690,900.00 | | |
| 8/1/2017 | Thomas G. Wiggans | CEO | Sell | 500 | $27.58 | $13,790.00 | | |
| 7/5/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.00 | $75,000.00 | | |
| 7/3/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $29.06 | $145,300.00 | | |
| 6/20/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.01 | $75,025.00 | | |
| 6/2/2017 | Thomas G. Wiggans | CEO | Sell | 5,000 | $27.52 | $137,600.00 | | |
| 5/15/2017 | Christopher M. Griffith | SVP | Sell | 1,312 | $27.07 | $35,515.84 | | |
| 4/17/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $33.97 | $44,262.91 | | |
| 4/3/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $33.53 | $83,825.00 | | |
| 4/3/2017 | Thomas G Wiggans | CEO | Sell | 8,000 | $33.49 | $267,920.00 | 14,468 | |
| 4/3/2017 | William R Ringo | Director | Sell | 500 | $34.03 | $17,015.00 | 500 | |
| 3/15/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $35.79 | $46,634.37 | | |
| 3/1/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $33.61 | $84,025.00 | | |
| 3/1/2017 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.54 | $368,940.00 | 17,468 | |
| 3/1/2017 | William R Ringo | Director | Sell | 500 | $35.09 | $17,545.00 | 500 | |
| 2/15/2017 | Christopher M. Griffith | SVP | Sell | 1,303 | $30.79 | $40,119.37 | | |
| 2/15/2017 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | 500 | |
| 2/14/2017 | Eugene A Bauer | Insider | Sell | 1,505 | $30.00 | $45,150.00 | | |
| 2/1/2017 | Eugene A Bauer | Insider | Sell | 995 | $30.00 | $29,850.00 | | |
| 1/17/2017 | Christopher M. Griffith | VP | Sell | 1,303 | $29.11 | $37,930.33 | | |
| 1/4/2017 | Thomas G Wiggans | CEO | Sell | 8,000 | $31.06 | $248,480.00 | 11,468 | |
| 1/4/2017 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | 500 | |
| 1/3/2017 | Eugene A Bauer | Insider | Sell | 2,500 | $30.07 | $75,175.00 | | |
| 12/16/2016 | William R Ringo | Director | Sell | 125 | $32.00 | $4,000.00 | 125 | |
| 12/15/2016 | Christopher M. Griffith | VP | Sell | 1,303 | $30.70 | $40,002.10 | | |
| 12/14/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $30.36 | $75,900.00 | | |
| 12/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $30.80 | $338,800.00 | | |
| 12/1/2016 | William R Ringo | Director | Sell | 375 | $32.00 | $12,000.00 | 375 | |
| 11/9/2016 | Andrew Guggenhime | CFO | Sell | 4,100 | $35.02 | $143,582.00 | 9,216 | |
| 11/9/2016 | William R Ringo | Director | Sell | 500 | $32.30 | $16,150.00 | 500 | |
| 11/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.19 | $343,090.00 | | |
| 10/17/2016 | Christopher M Griffith | VP | Sell | 1,303 | $32.33 | $42,125.99 | 45,165 | |
| 10/11/2016 | Andrew Guggenhime | CFO | Sell | 10,900 | $34.34 | $374,306.00 | 16,016 | |
| 10/3/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $34.60 | $380,600.00 | | |
| 10/3/2016 | William R Ringo | Director | Sell | 500 | $34.25 | $17,125.00 | 500 | |
| 9/19/2016 | Andrew Guggenhime | CFO | Sell | 15,000 | $35.01 | $525,150.00 | 20,116 | |
| 9/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $33.26 | $43,337.78 | 45,165 | |
| 9/12/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $32.53 | $325,300.00 | 15,116 | |
| 9/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.63 | $347,930.00 | | |
| 9/1/2016 | William R Ringo | Director | Sell | 500 | $32.00 | $16,000.00 | 500 | |
| 8/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $31.75 | $41,370.25 | 44,941 | |
| 8/11/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $31.02 | $310,200.00 | 14,375 | |
| 8/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $33.18 | $82,950.00 | | |
| 8/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.19 | $365,090.00 | | |
| 8/1/2016 | William R Ringo | Director | Sell | 500 | $33.65 | $16,825.00 | 500 | |
| 7/15/2016 | Christopher M Griffith | VP | Sell | 1,303 | $30.02 | $39,116.06 | 44,941 | |
| 7/11/2016 | Andrew Guggenhime | CFO | Sell | 10,000 | $30.15 | $301,500.00 | 14,375 | |
| 7/5/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $29.62 | $325,820.00 | | |
| 7/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $29.48 | $73,700.00 | | |
| 6/23/2016 | Luis C Pena | Insider | Sell | 10,000 | $30.01 | $300,100.00 | 14,653 | |
| 6/15/2016 | Luis C Pena | Insider | Sell | 10,000 | $29.47 | $294,700.00 | 7,653 | |
| 6/13/2016 | Christopher M Griffith | VP | Sell | 4,405 | $30.16 | $132,854.80 | 48,043 | |
| 6/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $31.65 | $79,125.00 | | |
| 6/1/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $31.57 | $347,270.00 | | |
| 5/2/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $25.09 | $62,725.00 | | |
| 5/2/2016 | Thomas G Wiggans | CEO | Sell | 9,000 | $25.11 | $225,990.00 | | |
| 4/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $20.84 | $52,100.00 | | |
| 4/1/2016 | Thomas G Wiggans | CEO | Sell | 7,000 | $20.69 | $144,830.00 | | |
| 3/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $22.55 | $56,375.00 | | |
| 3/1/2016 | Thomas G Wiggans | CEO | Sell | 7,000 | $22.57 | $157,990.00 | | |
| 2/1/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $27.26 | $68,150.00 | | |
| 2/1/2016 | Thomas G Wiggans | CEO | Sell | 9,000 | $27.25 | $245,250.00 | | |
| 1/4/2016 | Eugene A Bauer | Insider | Sell | 2,500 | $33.17 | $82,925.00 | | |
| 1/4/2016 | Thomas G Wiggans | CEO | Sell | 11,000 | $33.17 | $364,870.00 | | |
| 12/1/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $29.65 | $74,125.00 | | |
| 11/2/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $27.82 | $69,550.00 | | |
| 10/1/2015 | Eugene A Bauer | Insider | Sell | 2,500 | $22.87 | $57,175.00 | | |
| 9/14/2015 | Eugene A Bauer | Insider | Sell | 22,500 | $28.05 | $631,125.00 | | |
| 11/25/2014 | Matthew K Fust | Director | Buy | 6,000 | $16.77 | $100,620.00 | | |
| 10/8/2014 | Bay City Capital Llc | Director | Buy | 69,112 | $16.00 | $1,105,792.00 | | |
(Data available from 1/1/2013 forward)
Dermira (NASDAQ DERM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Christopher Horan Joins Dermira as Chief Technical Operations Officer
finance.yahoo.com - April 19 at 5:20 PM |
 | Dermira (DERM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 11:30 AM |
| Dermira (DERM) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 17 at 9:57 AM |
| Dermira (DERM) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 7:21 AM |
 | Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment ...
globenewswire.com - April 13 at 5:14 PM |
| Recent Analysis Shows Landmark Infrastructure Partners LP, Laureate Education, MDC Partners, Pzena Investment Management, Dermira, and MediciNova Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - April 12 at 9:14 AM |
| Zacks: Analysts Expect Dermira (DERM) to Announce -$1.29 EPS
www.americanbankingnews.com - April 11 at 1:08 AM |
| BidaskClub Downgrades Dermira (DERM) to Strong Sell
www.americanbankingnews.com - April 10 at 10:00 PM |
| Dermira (DERM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 10:24 AM |
| Dermira (DERM) Given a $20.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 9 at 8:25 AM |
| Dermira's (DERM) Buy Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - April 1 at 4:16 PM |
| Dermira (DERM) Given "Outperform" Rating at Leerink Swann
www.americanbankingnews.com - April 1 at 3:42 PM |
| Dermira (DERM) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 31 at 4:56 PM |
| BidaskClub Downgrades Dermira (DERM) to Hold
www.americanbankingnews.com - March 30 at 9:27 AM |
| Cantor Fitzgerald Reaffirms "Buy" Rating for Dermira (DERM)
www.americanbankingnews.com - March 27 at 9:31 AM |
| Dermira (DERM) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - March 26 at 2:30 PM |
| Q1 2018 Earnings Forecast for Dermira Inc (DERM) Issued By Leerink Swann
www.americanbankingnews.com - March 26 at 1:04 AM |
| Dermira (DERM) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 25 at 3:12 PM |
| Dermira Inc (DERM) Expected to Announce Earnings of -$1.29 Per Share
www.americanbankingnews.com - March 25 at 3:12 AM |
| BidaskClub Lowers Dermira (DERM) to Sell
www.americanbankingnews.com - March 24 at 1:11 PM |
| Dermira Inc (DERM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 11:56 AM |
| Dermira (DERM) Downgraded by Guggenheim
www.americanbankingnews.com - March 24 at 11:24 AM |
| Dermira's (DERM) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - March 24 at 10:49 AM |
| Dermira (DERM) vs. Fibrocell Science (FCSC) Financial Review
www.americanbankingnews.com - March 23 at 3:26 AM |
| Dermira to Present at 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 20 at 8:51 AM |
| Dermira (DERM) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 17 at 6:14 PM |
| Dermira (DERM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 16 at 8:21 PM |
| Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer
finance.yahoo.com - March 14 at 6:40 PM |
| FY2018 EPS Estimates for Dermira Inc Lowered by Analyst (DERM)
www.americanbankingnews.com - March 9 at 10:35 AM |
| Dermira (DERM) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 8 at 9:58 PM |
| Dermira Inc (DERM) Expected to Post Q1 2018 Earnings of ($1.40) Per Share
www.americanbankingnews.com - March 8 at 6:28 AM |
| Dermira Reminds Investors What Binary Means in Biotech
finance.yahoo.com - March 6 at 5:25 PM |
| US Stocks Reverse Losses
finance.yahoo.com - March 6 at 5:25 PM |
| Here's Why Dermira Fell as Much as 64.2% Today
finance.yahoo.com - March 6 at 5:25 PM |
| Why This Biotech Stock Just Lost Two-Thirds Of Its Value
finance.yahoo.com - March 6 at 5:25 PM |
| Dermira (DERM) Price Target Cut to $19.00
www.americanbankingnews.com - March 6 at 3:29 PM |
| Here’s What Really Just Happened With Dermira, Inc. (NASDAQ:DERM)
finance.yahoo.com - March 6 at 8:36 AM |
| AWM Investment Company Inc. Has $2.80 Million Stake in Dermira Inc (DERM)
www.americanbankingnews.com - March 6 at 4:45 AM |
 | Dermira (DERM) Says Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
www.streetinsider.com - March 5 at 5:36 PM |
 | Dermira abandons acne drug
www.reuters.com - March 5 at 5:36 PM |
 | Why Dermira Shares Are Getting Crushed
247wallst.com - March 5 at 5:36 PM |
| Dermira Inc (DERM) Runs Downhill on Back of Disappointing Clinical Results in Acne Vulgaris
finance.yahoo.com - March 5 at 5:36 PM |
| Dermira (DERM) Rating Lowered to Neutral at Mizuho
www.americanbankingnews.com - March 5 at 1:58 PM |
| Cowen Analysts Give Dermira (DERM) a $25.00 Price Target
www.americanbankingnews.com - March 5 at 1:36 PM |
 | Dermira Inc Stock Plunges on Acne Drug Failure
investorplace.com - March 5 at 1:19 PM |
| Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
finance.yahoo.com - March 5 at 8:40 AM |
| Dermira shares plummet 70% on news of acne drug failure
finance.yahoo.com - March 5 at 8:40 AM |
| Dermira Inc (DERM) Director Sells $15,510.00 in Stock
www.americanbankingnews.com - March 2 at 7:36 PM |
| Dermira Inc (DERM) Insider Eugene A. Bauer Sells 500 Shares
www.americanbankingnews.com - March 2 at 7:34 PM |
| Cantor Fitzgerald Brokers Lift Earnings Estimates for Dermira Inc (DERM)
www.americanbankingnews.com - February 28 at 12:04 PM |
Dermira (NASDAQ:DERM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dermira (NASDAQ:DERM) Income Statement, Balance Sheet and Cash Flow Statement
Dermira (NASDAQ DERM) Stock Chart for Friday, April, 20, 2018
Loading chart…
